(Q52880827)

9 May 2018

editorial

0 references

title

Something rotten in the state of clinical and economic evaluations? (English)

1 reference

9 May 2018

author name string

Freemantle N

series ordinal

1

1 reference

9 May 2018

Maynard A

series ordinal

2

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 March 1994

1 reference

9 May 2018

published in

Health Economics

1 reference

9 May 2018

volume

3

1 reference

9 May 2018

page(s)

63-67

1 reference

9 May 2018

issue

2

1 reference

9 May 2018

The scandal of poor medical research

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

Clinical biostatistics. Bailar's laws of data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

The medical review article: state of the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

Conflict of interest and the BMJ

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

The cost-benefit approach

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Publication bias in clinical research

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Getting to grips with Archie Cochrane's agenda

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Fraud, distortion, delusion, and consensus: the problems of human and natural deception in epidemiologic science

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Economic analysis in randomized control trials

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Consensus conferences as drug promotion

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030202

7 January 2021

Identifiers

DOI

10.1002/HEC.4730030202

1 reference

9 May 2018

PubMed ID

7880237

1 reference

9 May 2018